- Home
- WIW vs PGEN Comparison
WIW vs PGEN Comparison
Compare WIW & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- PGEN
- Stock Information
- Founded
- WIW 2004
- PGEN 1998
- Country
- WIW United States
- PGEN United States
- Employees
- WIW N/A
- PGEN N/A
- Industry
- WIW Finance Companies
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- WIW Finance
- PGEN Health Care
- Exchange
- WIW Nasdaq
- PGEN Nasdaq
- Market Cap
- WIW 537.8M
- PGEN 454.6M
- IPO Year
- WIW N/A
- PGEN N/A
- Fundamental
- Price
- WIW $8.61
- PGEN $1.33
- Analyst Decision
- WIW
- PGEN Strong Buy
- Analyst Count
- WIW 0
- PGEN 4
- Target Price
- WIW N/A
- PGEN $7.33
- AVG Volume (30 Days)
- WIW 229.9K
- PGEN 1.2M
- Earning Date
- WIW 01-01-0001
- PGEN 05-20-2025
- Dividend Yield
- WIW 11.14%
- PGEN N/A
- EPS Growth
- WIW N/A
- PGEN N/A
- EPS
- WIW N/A
- PGEN N/A
- Revenue
- WIW N/A
- PGEN $3,925,000.00
- Revenue This Year
- WIW N/A
- PGEN $189.12
- Revenue Next Year
- WIW N/A
- PGEN $1,093.07
- P/E Ratio
- WIW N/A
- PGEN N/A
- Revenue Growth
- WIW N/A
- PGEN N/A
- 52 Week Low
- WIW $8.01
- PGEN $0.65
- 52 Week High
- WIW $9.37
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- WIW 51.01
- PGEN 39.77
- Support Level
- WIW $8.58
- PGEN $1.23
- Resistance Level
- WIW $8.66
- PGEN $1.66
- Average True Range (ATR)
- WIW 0.07
- PGEN 0.11
- MACD
- WIW 0.01
- PGEN -0.01
- Stochastic Oscillator
- WIW 57.89
- PGEN 23.26
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.